ImmuneResearch Market

Thymagen

A synthetic dipeptide (Glu-Trp) from the Khavinson bioregulator family, studied for thymic bioregulation and immune system support in aging.

ImmuneThymusBioregulatorKhavinson

Also referenced as: EW, Glu-Trp, Thymogen

Also appears in: Longevity

Price compare
11 tracked offers across 11 vendors · 8 dosages
Best trust-adjusted value: Mile High Compounds · Strong trust · $1.53/mg
From
$1.53/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

Flatvs. Aug 10
Current low$1.80/mg
Market median$2.75/mg
Current coverage5 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Thymagen crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence10 certificate records mentioning this compound or product name6 provider-linked · 5 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Immune / inflammation research

Primary research area: Immune. Also surfaces under Longevity for browsing and discovery.

Aliases
3

EW, Glu-Trp, Thymogen

Signal depth
Medium

No FDA label signal · 209 trials · 3196 PubMed results

Preclinical
Research evidence

Current evidence for Thymagen is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Thymagen has no clinical trials that name it and 3196 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
Established
Journal of Agricultural and Food Chemistry · 50 citationsWhey Protein Peptide Pro-Glu-Trp Ameliorates Hyperuricemia by Enhancing Intestinal Uric Acid Excretion, Modulating the Gut Microbiota, and Protecting the Intestinal Barrier in RatsHypertension · 31 citationsMechanism of angiotensin I converting enzyme inhibition by SQ20,881 (less than Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) in vivo. Further evidence for extrapulmonary conversion.Drug Design Development and Therapy · 16 citationsGlu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbitsJournal ArticleAcid-responsive natural amphiphile self-assembled nanoparticles with enhanced biointerface performance for tomato gray mold management.Journal ArticleSurface Proton Reservoirs Constrain Alkalinity Export from Enhanced Weathering.Journal ArticleEfficient Computation of Physical Charging Free Energies for Monatomic Ions at Any Charge along Alchemical Charging Pathways.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is Thymagen?

Thymagen (also marketed as Thymogen) is a synthetic dipeptide with the sequence Glu-Trp (EW), classified as a thymic bioregulator within the Khavinson peptide framework. It is related to Thymalin (the full thymic extract) and Vilon (KE dipeptide) but uses a different amino acid pair proposed to have overlapping thymic effects.

How it works

  • Thymic support — proposed to modulate gene expression in thymic epithelial cells, supporting T-lymphocyte maturation and thymic function during aging (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
  • Immune reconstitution — Thymogen has been studied in the context of immunodeficiency states and post-radiation immune recovery in Russian clinical literature

Research status

  • Thymogen (the EW dipeptide) has Russian regulatory approval as an immunomodulator (nasal spray formulation)
  • Morozov & Khavinson (1997) reviewed the immunomodulatory effects of thymic peptide preparations (Immunology Letters, 55(1):1–4)
  • Khavinson (2005) included Thymagen in the broader bioregulator review (Gerontology, 51(2):70–75)
  • Clinical data exists primarily in Russian-language literature

Key considerations

  • One of the few Khavinson bioregulators with any form of regulatory approval (Russian market)
  • Overlaps functionally with Vilon (KE) and Thymalin — all three target thymic/immune function
  • Available from research vendors as lyophilized powder, capsules, or nasal spray
  • The EW dipeptide has slightly more published clinical data than most other Khavinson short peptides